CYP2C19 enzyme

Citalopram and the enzyme CYP2C19

Citalopram is processed within the body primarily by the enzyme CYP2C19. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of citalopram and the risk of side effects can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with citalopram.

Clopidogrel and the enzyme CYP2C19

Clopidogrel is a drug that first needs to be metabolised into an active component within the body. The enzyme CYP2C19 plays an important role in this process.

The activity of this enzyme can, however, vary considerably depending on your genetic predisposition, which means the availability of the active component of clopidogrel can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds to opt for an alternative anticoagulant.

Imipramine and the enzymes CYP2C19 and CYP2D6

Imipramine is processed to a large extent by the enzymes CYP2C19 and CYP2D6.

Initially, imipramine is metabolised (demethylated) by the enzyme CYP2C19 into another active substance. The enzymes CYP1A2 and CYP3A4 are also involved in this step to a lesser extent. After this activation step this substance is metabolised further (hydroxylated) by the enzyme CYP2D6 into less active components.

The activity of the enzymes concerned can vary considerably depending on your genetic predisposition, which means the efficacy of imipramine can also differ from person to person. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with imipramine.

Mavacamten and the enzyme CYP2C19

Mavacamten is processed within the body primarily by the enzyme CYP2C19 and to a lesser extent by CYP3A4. The activity of the CYP2C19 enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of mavacamten and the risk of side effects can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with mavacamten.

Omeprazole and the enzyme CYP2C19

Omeprazole is processed within the body primarily by the enzyme CYP2C19. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of omeprazole can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with omeprazole.

Sertraline and the enzyme CYP2C19

Sertraline is processed within the body primarily by the enzyme CYP2C19. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of sertraline and the risk of side effects can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with sertraline.